Ocunexus Therapeutics

Ocunexus Therapeutics is a biopharmaceutical company that develops therapeutics for unmet clinical needs in ophthalmology. The company specializes in developing highly differentiated drug candidates based upon a novel mechanism of action called “Gap Junction Channel Modulation.” It has developed treatments for multiple front- and back-of-the-eye diseases and disorders that would potentially alter the standard of care. In addition, the company's technologies are expected to be transferable to other acute and chronic disease indications.

Ocunexus is formerly known as CoDa Therapeutics, a pharmaceutical company focused on the development and commercialization of wound care therapeutics based on gap junction modulation. The company is based in San Diego, California.

Ocunexus Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $12.6B in funding across 160 round(s). With a team of 1-10 employees, Ocunexus Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Ocunexus Therapeutics, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.